drugset / Trial / NCT05850871
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
Non-randomizedSingle-groupSingle-blindTreatment
Summary
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes
Timeline
- Start
- 2023-01-06
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aztreonam | Small molecule | 2 g | — |
| Subject | Ceftazidime-avibactam | Other / unclassified | 2.5 g | — |
Indications
No indication recorded.